Biosimilars can be used in place of a branded drug (if one exists), offering the sponsor a variety of benefits. But what is a biosimilar, exactly? Can a sponsor just replace the branded drug with the biosimilar, or are there certain requirements that need to be met in order to use it in a clinical trial?

Summary: Watch this webinar to learn more about available options within demand-led supply and how they can support clinical trials, especially decentralized studies.

Summary: This executive summary showcases examples of real-life tactical and operational decisions involved in the integrated approach to drug development.

Summary: The growing complexity associated with today’s clinical trials is driving sponsors to deploy non-traditional clinical supply strategies to address their changing needs. This session will explore several alternative clinical supply models, use cases and identify key considerations when adopting one of these models.

Summary: Watch this webinar to learn how to objectively evaluate and decide whether it is the EU or the UK that best aligns with your clinical supply strategy.

Summary: Discover Catalent's expert team and their vital role in ensuring timely delivery of investigational medicinal products for successful clinical supply projects.

Summary: As the development pipeline for new drugs grows, explore approaches to expedite drug development and integrate clinical supply effectively.

Summary: Learn about the MRCT trends in studies from China to overseas, as well as how clinical supply strategy considerations in different clinical phases can help in understanding risk assessment when developing a global supply plan.

Find out when to consider Case Management Services for your cell or gene therapy project

Summary: This webinar addresses the main steps and process to help proactively mitigate risks and optimize the clinical supply chain.